Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an announcement.
On October 28, 2025, bioAffinity Technologies announced that the Australian Patent Office accepted its patent application for a platform technology to assess lung health and predict multiple lung diseases. This acceptance strengthens bioAffinity’s global patent portfolio, enhancing its market positioning and protecting its core technology, which is crucial for the CyPath® Lung test and other diagnostics in development.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is primarily driven by the company’s weak financial performance and poor technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage cancer and lung diseases, with its flagship product being CyPath® Lung, a test for lung cancer.
Average Trading Volume: 2,803,777
Technical Sentiment Signal: Sell
Current Market Cap: $11.92M
For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.